Preexisting tumor-resident T cells with cytotoxic potential associate with response to neoadjuvant anti–PD-1 in head and neck cancer
Giacomo Oliveira(Dana-Farber Cancer Institute), Ravindra Uppaluri(Dana-Farber Cancer Institute), Jason T. Rich(Washington University in St. Louis), Vickie Y. Jo(Brigham and Women's Hospital), Rebecca D. Chernock(Washington University in St. Louis), Sidharth V. Puram(Washington University in St. Louis), Ann Marie Egloff(Brigham and Women's Hospital), Jonathan D. Schoenfeld(Brigham and Women's Hospital), Jacquelyn O. Wolff(Dana-Farber Cancer Institute), Dorina Kallogjeri(Washington University in St. Louis), Jay F. Piccirillo(Washington University in St. Louis), Laura A. Goguen(Brigham and Women's Hospital), Glenn J. Hanna(Dana-Farber Cancer Institute), Patrik Pipkorn(Washington University in St. Louis), Zexiang Zeng(Dana-Farber Cancer Institute), Livius Penter(Dana-Farber Cancer Institute), Donald J. Annino(Harvard University), José P. Zevallos(University of Pittsburgh Medical Center), Cameron Messier(Dana-Farber Cancer Institute), Catherine J. Wu(Dana-Farber Cancer Institute), Lara Dunn(Memorial Sloan Kettering Cancer Center), Cloud P. Paweletz(Massachusetts General Hospital), Kari Stromhaug(Dana-Farber Cancer Institute), Scott J. Rodig(Brigham and Women's Hospital), Douglas R. Adkins(Washington University in St. Louis), Jingxin Fu(Tongji University), Randal C. Paniello, Patrick H. Lizotte(Harvard University), Mena Mansour(The University of Texas MD Anderson Cancer Center), Kathleen L. Pfaff(Dana-Farber Cancer Institute), Gavin P. Dunn(Brigham Young University), Robert I. Haddad(Georgetown University), Luc G.T. Morris(Memorial Sloan Kettering Cancer Center), Alexander B. Afeyan(Harvard University), Peter Oppelt(Washington University in St. Louis), Liye Zhou(Dana-Farber Cancer Institute), Jessica Ley(Washington University in St. Louis), J. C. Webb(Dana-Farber Cancer Institute), Ryan S. Jackson(Washington University in St. Louis)
Cited by 118
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Head and Neck Cancer
|Cell|2017|2.6k
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
|Cell|2018|2k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k